Supriya Lifescience Limited delivered a steady performance in Q3 FY26, reporting revenue of INR206 crores with 11% year-on-year growth. The pharmaceutical company maintained strong profitability metrics while advancing its product launch pipeline and facility expansion plans during the quarter ended December 31, 2025.

Financial Performance Highlights

The company's quarterly results demonstrated consistent operational execution across key financial metrics:

For the nine-month period, revenue stood at INR551 crores compared to INR512 crores in 9M FY25, reflecting 8% year-on-year growth. EBITDA reached INR196 crores against INR193 crores in the previous year, with margins maintained at 36% for 9M FY26.

Export Markets Drive Growth

Exports remained the cornerstone of the company's revenue strategy, contributing 82% of Q3 revenues. The geographic diversification showed positive momentum with Latin America delivering healthy growth and accounting for 24% of quarterly revenues. North America contributed 6% to total revenues, with both regions demonstrating increased overall revenue contribution during the quarter.

The company's backward integration initiatives continued to strengthen its cost structure, with 74% of revenues coming from backward integrated products. This strategic focus supports sustainable growth while enhancing operational efficiency across the product portfolio.

Product Launch Pipeline Progress

Supriya Lifescience successfully executed its planned product launches during Q3 FY26. The company launched a key cardiovascular product expected to contribute meaningfully in Q4 FY26, along with an ADHD product anticipated to scale up over coming quarters. The liquid anaesthetics product has been commercialized with steady monthly supplies underway.

Development activities for the contrast media product continue progressing as planned, supporting the company's strategy of introducing 3-4 new products annually. These launches align with the company's focus on high-margin niche offerings across core therapeutic segments including anesthetics, anti-diabetics, anti-anxiety medications, vitamins, and ADHD treatments.

Facility Development and Expansion

The Ambernath facility reached a significant milestone, becoming ready for capitalization in Q4 FY26. This development marks the completion of commissioning and readiness for sustained commercial operations, representing a key advancement for the company's CDMO segment.

Capex for Q3 FY26 stood at INR28 crores, while nine-month capex reached INR71 crores, primarily directed toward the Ambernath facility. Management expects remaining FY26 capex of approximately INR15 crores, focused on maintenance capex and specific projects including the Ribo Block and formulation plant requirements.

Management Guidance and Outlook

Management reaffirmed its guidance of approximately 20% annual revenue growth and EBITDA margins of 33-35%. The company remains confident in its progress toward the INR1,000 crores revenue milestone for FY27, supported by a healthy pipeline of planned launches and steady demand across core therapeutic segments.

Dr. Satish Wagh, Executive Chairman, emphasized the company's strategic positioning: "Our focus on operational efficiency and high-margin niche offerings have delivered strong execution. We remain focused on scaling our presence in regulated markets and reinforcing our competitive position through backward integration, strong regulatory capabilities and a diverse product portfolio."

Supriya Lifescience Limited's Board of Directors approved the company's unaudited financial results for Q3 FY26 and made significant governance changes, including the appointment of two new independent directors and reconstitution of board committees. The pharmaceutical company demonstrated robust operational performance with double-digit revenue growth while advancing strategic initiatives.

Board Meeting Outcomes and Financial Results Approval

The Board of Directors convened on February 09, 2026, to approve the unaudited financial results for the quarter and nine months ended December 31, 2025. The meeting, which commenced at 3:00 PM and concluded at 5:00 PM, addressed key governance and financial matters under Regulation 30 of SEBI (LODR) Regulations, 2015.

Financial Performance Highlights

The company's Q3 FY26 financial results demonstrated strong growth momentum across key performance metrics:

For the nine-month period ended December 31, 2025, revenue from operations reached ₹5,513.47 Mn compared to ₹5,123.76 Mn in the corresponding previous period, representing growth of 7.6%.

Key Director Appointments

The board approved significant changes to its composition with the appointment of two new independent directors:

Mr. Manish Panchal brings over 32 years of cross-industry experience spanning chemicals, logistics, pharmaceuticals, and healthcare sectors. His expertise includes strategy, operational excellence, business development, and investment banking. Mr. Kothandaraman Hari contributes 28 years of capital markets experience, having served as Executive Vice President at NSE, leading strategic initiatives across multiple asset classes.

Board Committee Reconstitution

Following the new appointments, the company reconstituted its key board committees:

Audit Committee:

• Mr. Hari K. (Chairman)
• Dr. Ganapati Dadasaheb Yadav (Member)
• Dr. Satish Waman Wagh (Member)
• Mr. Manish Panchal (Member)

Nomination and Remuneration Committee:

• Mr. Hari K. (Chairman)
• Dr. Sunil Subhash Bhagwat (Member)
• Mr. Manish Panchal (Member)

Stakeholders' Relationship Committee:

• Mr. Manish Panchal (Chairman)
• Dr. Saloni Satish Wagh (Member)
• Dr. Satish Waman Wagh (Member)

Independent Director Re-appointment

The board also approved the re-appointment of Dr. Neelam Yashpal Arora (DIN: 01603068) as Non-Executive Independent Woman Director for a second consecutive term of five years, effective from March 25, 2026, to March 24, 2031, subject to shareholder approval. Dr. Arora brings over 31 years of teaching experience and 10 years of administrative experience in education, with expertise in commerce, taxation, economics, and law.

Cost Structure and Exceptional Items

The company reported an exceptional item of ₹4.58 Mn related to the impact of New Labour Codes implemented by the Government of India effective November 21, 2025. The codes consolidate 29 existing labour legislations into four unified frameworks covering wages, social security, industrial relations, and occupational safety.